USPTO serial 79132921
TETRAVARINEX
Reviewed by CopyMark Law Group
Reg. 4582222Status 709
- Filing date
- Status date
- Registration date
- Aug 12, 2014
- Examiner
- REEVES, APRIL ELIZABETH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with TETRAVARINEX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Salisbury, Wiltshire SP4 0JQ, GB
Salisbury, Wiltshire SP4 0JQ, GB
Jazz Pharmaceuticals Research UK Limited
GB
Other trademarks owned by Jazz Pharmaceuticals Research UK Limited
GB
GB
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and veterinary pharmaceutical preparations, namely, herbs, herbal extracts, formulas containing herbal extracts, medicinal oils and pure extracts of medicinal plants and herbs, for use in the treatment of pain, multiple sclerosis, neuropathic pain, spinal cord injury, bladder disfunction, peripheral neuropathy, cancer pain, peri-operative pain, rheumatoid arthritis, inflammatory bowel disease, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, epilepsy, dravet syndrome, neonatal hypoxia, seizures, alzheimers, bone disorders, drug, alcohol and nicotine abuse, inflammatory disorders, protection of pancreatic islet cells in the treatment of diabetic or pre-diabetic patients, protection of beta cells in the treatment of diabetic or pre-diabetic patients, maintenance of insulin levels, improved control of blood glucose levels, treatment of type I diabetes, treatment of type II diabetes; pharmaceutical and veterinary pharmaceutical preparations for the treatment of pain, multiple sclerosis, neuropathic pain, spinal cord injury, bladder disfunction, peripheral neuropathy, cancer pain, peri-operative pain, rheumatoid arthritis, inflammatory bowel disease, neurogenic symptoms, psychotic disorders, diseases of the central nervous system, stroke and head injury, motion sickness and chemically induced sickness, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases, metabolic disorders, obesity, obesity associated with type II diabetes, bulimia, schizophrenia, epilepsy, dravet syndrome, neonatal hypoxia, seizures, alzheimers, bone disorders, drug, alcohol and nicotine abuse, inflammatory disorders, protection of pancreatic islet cells in the treatment of diabetic or pre-diabetic patients, protection of beta cells in the treatment of diabetic or pre-diabetic patients, maintenance of insulin levels, improved control of blood glucose levels, treatment of type I diabetes, treatment of type II diabetes; herbs for medicinal purposes; herb teas for medicinal purposes; plant extracts for pharmaceutical purposes | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by GW Pharma Limited
- Other trademarks owned by GW Pharma Limited
- Other trademarks owned by Jazz Pharmaceuticals Research UK Limited
- Other trademarks owned by GW Pharma Limited
- Other trademarks owned by GW Research Limited
- Other trademarks in Class 005
- Similar marks named TETRAVARINEX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 11, 2025 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 30, 2023 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Dec 28, 2022 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Dec 28, 2022 | INPC | INVALIDATION PROCESSED | — |
| Nov 24, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 26, 2021 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Feb 26, 2021 | C71T | CANCELLED SECTION 71 | — |
| Oct 9, 2019 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Aug 12, 2019 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Sep 13, 2018 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Dec 21, 2017 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 29, 2017 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 29, 2017 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 15, 2016 | RNWL | INTERNATIONAL REGISTRATION RENEWED | — |
| Sep 24, 2015 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jun 19, 2015 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 30, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jan 6, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jan 6, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 12, 2014 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 12, 2014 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 13, 2014 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| May 27, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 27, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 7, 2014 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 7, 2014 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 7, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 22, 2014 | PBPR | WITHDRAWN FROM PUB - ESU SUPERVISOR REQUEST | — |
| Apr 22, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 18, 2014 | ALIE | ASSIGNED TO LIE | — |
| Mar 28, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 24, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 24, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 24, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 2, 2014 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 2, 2014 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 20, 2013 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 25, 2013 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 25, 2013 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 24, 2013 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 23, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 15, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 26, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 22, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 18, 2013 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |